Iovance Biotherapeutics (NASDAQ:IOVA) saw its shares climb 12.5% on Thursday, closing at $8.99, as trading volume more than doubled its typical daily average. The stock reached an intraday high of $9.36, marking a new 52-week peak. The surge added approximately $452 million to the company's market capitalization, which now stands at $4.06 billion.
The rally was fueled by a price target revision from UBS, which lifted its target to $7 from $4 while maintaining a Neutral stance. However, the new target remains 22% below the current trading price, highlighting the disconnect between analyst expectations and the market's enthusiasm. Mizuho also raised its target to $11 from $10, maintaining an Outperform rating, citing improved adoption and expansion of the treatment-center network.
Despite the strong price action, the consensus price target from nine analysts sits at $9.22, only 2.6% above Thursday's close. The breakdown is seven Buy ratings, two Hold, and zero Sell. This suggests that further upside may be limited unless the company delivers on its operational momentum.
Operationally, Iovance reported second-quarter revenue of $99.3 million, a 66% year-over-year increase and a 39% sequential gain. Gross margin improved to 56%, up from 41% in the first quarter, as fixed manufacturing costs were spread over a larger production base. Amtagvi, the company's lead therapy, accounted for roughly 92% of revenue, with U.S. sales reaching about $91 million.
Interim CEO Frederick Vogt commented, "Second-quarter revenue reached a record $99.3 million with gross margin of 56%, driven by continued U.S. Amtagvi demand." The company's authorized network now includes over 95 treatment centers across three regions, with plans to reach at least 110 active sites by year-end. The 31-day manufacturing process remains a critical factor in capacity and profitability.
Valuation metrics have tightened. The market capitalization of $4.06 billion is approximately 12.5 times trailing revenue of $325 million, and 11.3 times the midpoint of the company's 2026 revenue guidance. The balance sheet provides some cushion, with cash and investments of about $304 million as of June 30, expected to fund operations into the latter half of 2028. However, the company still reported a net loss of $47.3 million in the quarter.
Looking ahead, Iovance is reassessing its full-year revenue forecast of $350 million to $370 million, with an update expected in the third quarter. First data from the lung cancer program is anticipated in the fourth quarter, and sarcoma data will be presented at the ESMO meeting in October. The stock has risen 28.8% since last Friday's close of $6.98.
Investors will be watching whether trading volume remains elevated in the coming weeks. A slowdown in analyst revisions could highlight the slim margin above the average target. The commercial recovery is real, but at $8.99, further gains depend on sustained revenue growth, margin expansion, and patient uptake rather than new price targets.
The company faces risks including complex manufacturing processes, potential reimbursement delays, and clinical setbacks. However, the strong second-quarter performance and expanding treatment network provide a solid foundation for continued growth.
